Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.61 |
| ▸ | TSHR | P16473 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.48 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.48 |
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 6/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 1-Heptanol SCHEMBL2461694 | 1.00 | LMNA (0.61) | LMNAALDH1A1HSD17B10TSHRMEN1 | |
| Nonanol SCHEMBL10363769 | 1.00 | LMNA (0.61) | LMNAALDH1A1HSD17B10TSHRMEN1 | |
| 1-Hexanol SCHEMBL537293 | 1.00 | LMNA (0.61) | LMNAALDH1A1HSD17B10TSHRMEN1 | |
| Cetyl Alcohol SCHEMBL7713541 | 1.00 | LMNA (0.61) | LMNAALDH1A1HSD17B10TSHRMEN1 | |
| 1-Hexanol SCHEMBL20395883 | 0.98 | ALDH1A1 (0.58) | LMNAALDH1A1HSD17B10TSHRMEN1 | |
| 1-Pentanol SCHEMBL3390919 | 0.98 | ALDH1A1 (0.64) | LMNAALDH1A1HSD17B10TSHRMEN1 | |
| Heptane SCHEMBL10663246 | 0.96 | ALDH1A1 (0.61) | LMNAALDH1A1HSD17B10TSHRMEN1 | |
| 1-Heptanol SCHEMBL8548655 | 0.94 | LMNA (0.54) | LMNAALDH1A1HSD17B10TSHRMEN1 | |
| 1-Pentanol SCHEMBL28324770 | 0.94 | ALDH1A1 (0.58) | LMNAALDH1A1HSD17B10TSHRMEN1 | |
| Hexane SCHEMBL5393958 | 0.93 | ALDH1A1 (0.64) | LMNAALDH1A1HSD17B10TSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023135259-A1 | SEMI-INTEGRATED METHOD FOR ENZYME-ASSISTED EXTRACTION AND PURIFICATION OF P-HYDROXYCINNAMIC ACIDS | INSTITUT NATIONAL DES SCIENCES ET INDUSTRIES DU VIVANT ET DE L'ENVIRONNEMENT (AGROPARISTECH) (FR) | 2023-07-20 | — | — | WO | disclosed |
| US-11117884-B2 | Potent gamma-secretase modulators | THE GENERAL HOSPITAL CORPORATION (US) | 2021-09-14 | — | — | US | disclosed |
| CN-107406423-B | Potent gamma-secretase modulators | 通用医疗公司 | 2020-06-16 | — | — | CN | disclosed |
| US-20200055840-A1 | POTENT GAMMA-SECRETASE MODULATORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-02-20 | — | — | US | disclosed |
| US-10472346-B2 | Potent gamma-secretase modulators | THE GENERAL HOSPITAL CORPORATION (US) | 2019-11-12 | — | — | US | disclosed |
| US-10408819-B2 | Luminescence-based methods and probes for measuring cytochrome P450 activity | PROMEGA CORPORATION (US) | 2019-09-10 | — | — | US | disclosed |
| US-20180093967-A1 | POTENT GAMMA-SECRETASE MODULATORS | THE GENERAL HOSPITAL CORPORATION | 2018-04-05 | — | — | US | disclosed |
| CN-107406423-A | Potent gamma secretase modulators | 通用医疗公司 | 2017-11-28 | — | — | CN | disclosed |
| EP-3212633-A1 | POTENT GAMMA-SECRETASE MODULATORS | The General Hospital Corporation (US) | 2017-09-06 | — | — | EP | disclosed |
| US-20170191985-A1 | LUMINESCENCE-BASED METHODS AND PROBES FOR MEASURING CYTOCHROME P450 ACTIVITY | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2017-07-06 | — | — | US | disclosed |
| US-6172061-B1 | AIDS THERAPY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-01-09 | — | — | US | disclosed |
| US-6166006-A | Anilide derivative, production and use thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-12-26 | — | — | US | disclosed |
| EP-1040103-A1 | ANILIDE DERIVATIVE, PRODUCTION AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2000-10-04 | — | — | EP | disclosed |
| EP-1039899-A2 | PHARMACEUTICAL COMPOSITION FOR ANTAGONIZING CCR5 COMPRISING ANILIDE DERIVATIVE | Takeda Chemical Industries, Ltd. (JP) | 2000-10-04 | — | — | EP | disclosed |
| WO-1999032100-A2 | PHARMACEUTICAL COMPOSITION FOR ANTAGONIZING CCR5 COMPRISING ANILIDE DERIVATIVE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-07-01 | — | — | WO | disclosed |
| WO-1999032468-A1 | ANILIDE DERIVATIVE, PRODUCTION AND USE THEREOF | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-07-01 | — | — | WO | disclosed |
| EP-0726896-A1 | 5-ARYLISOXAZOL-4-YL-SUBSTITUTED 2-AMINO CARBOXYLIC ACID COMPOUNDS | H. LUNDBECK A/S (DK) | 1996-08-21 | — | — | EP | disclosed |
| WO-1995012587-A1 | 5-ARYLISOXAZOL-4-YL-SUBSTITUTED 2-AMINO CARBOXYLIC ACID COMPOUNDS | H. LUNDBECK A/S (DK) | 1995-05-11 | — | — | WO | disclosed |
| EP-0535192-A1 | NOVEL DNA GYRASE INHIBITORS, PROCESS FOR THEIR MANUFACTURE AND PHARMACEUTICAL PREPARATIONS CONTAINING SAME. | HOFFMANN LA ROCHE (CH) | 1993-04-07 | — | — | EP | disclosed |
| US-4826851-A | 2-substituted ergoline urea and thio-urea derivatives having neurolyptic/dopaminergic activity | SCHERING AKTIENGESELLSCHAFT (DE) | 1989-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200055840-A1 | POTENT GAMMA-SECRETASE MODULATORS | BACE1, BACE2, GSAP | LMNA 2265/4885ALDH1A1 2818/4885HSD17B10 2261/4885 |
| US-10472346-B2 | Potent gamma-secretase modulators | BACE1, BACE2, APP | LMNA 694/4885ALDH1A1 2207/4885HSD17B10 1055/4885 |
| US-11117884-B2 | Potent gamma-secretase modulators | BACE1, BACE2, GSAP | LMNA 2265/4885ALDH1A1 2818/4885HSD17B10 2261/4885 |
| US-10408819-B2 | Luminescence-based methods and probes for measuring cytochrome P450 activity | CYP3A7, CYP3A43, CYP3A5 | LMNA 696/4885ALDH1A1 309/4885HSD17B10 528/4885 |
| US-20180093967-A1 | POTENT GAMMA-SECRETASE MODULATORS | BACE1, BACE2, APP | LMNA 694/4885ALDH1A1 2207/4885HSD17B10 1055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.